Rutgers Cancer Institute of New Jersey
The Rutgers Cancer Institute of New Jersey (RCINJ) is a cancer treatment and research institution that is a part of Rutgers University and located in New Brunswick, New Jersey. RCINJ is one of only 47 Comprehensive Cancer Centers in the nation designated by the National Cancer Institute and the only one in New Jersey.
The Rutgers Cancer Institute of New Jersey is an Institute of Rutgers Biomedical and Health Sciences at Rutgers University and is located adjacent to Robert Wood Johnson University Hospital, which serves as its primary clinical affiliate. RCINJ delivers comprehensive cancer care to both adults and children and conducts laboratory, clinical, prevention, and population research. Laboratory research at RCINJ is supported by more than $99 million annually in cancer-related research grants. RCINJ manages more than 80,000 patient visits annually.
Facilities
Recent additions to the facility have tripled the square footage to 225,000 square feet (20,900 m2), and the patient care setting was reconfigured to give it the feel of a much smaller institution. RCINJ provides a Resource and Learning Center, where patients and their families can review the latest information on advanced therapies and new clinical trials.
Current Leadership
The interim director of the Rutgers Cancer Institute of New Jersey is Bruce Haffty, MD.
In January 2017, Steven K. Libutti, MD, FACS will become the third permanent Director of RCINJ.
Past Permanent Directors
William N. Hait, MD, PhD 1993-2007
Robert S. DiPaola, MD 2008-2016
External links
Coordinates: 40°29′46″N 74°26′52″W / 40.496183°N 74.447916°W